The Weight Loss Atlas

Trial results explorer

Pick a trial and enter your weight to see what its group average would look like in pounds, side by side with placebo. This is a translation of published numbers, not a forecast of your own result.

Units

Leave the weight blank to see the percent changes only.

Pick a trial to see its results.

How to read this. A trial reports the average change for a whole group. Applying that average to one weight gives an illustration. People in the same trial ranged from little change to far more than the average. The "also reported" box shows how many people reached 5, 10, 15 and 20 percent where the paper gives it. Most of these trials gave lifestyle support to every group, which is why placebo groups also lose some weight.

Want to see your own change?

This page shows what trial groups lost. To work out your own percent change, set it beside a trial, or keep a private log of your weights, use My weight change.

All trials in one table

Show the table
TrialGroups and average change
Diethylpropion 12-month trial (Brazil)
Diethylpropion, 26 weeks		Diethylpropion 50 mg twice daily: −9.8%
Placebo (placebo): −3.2%
COR-I
Naltrexone and bupropion, 56 weeks		Naltrexone 16 mg plus bupropion 360 mg daily: −5.0%
Naltrexone 32 mg plus bupropion 360 mg daily: −6.1%
Placebo (placebo): −1.3%
ATTAIN-1
Orforglipron, 72 weeks		Orforglipron, lowest dose arm: −7.5%
Orforglipron, middle dose arm: −8.4%
Orforglipron, highest dose arm: −11.2%
Placebo (placebo): −2.1%
Low-dose phentermine before weight-loss surgery
Phentermine, 14 weeks		Lomaira (phentermine) 8 mg, three times daily: −4.7%
Placebo (placebo): −1.1%
CONQUER
Phentermine and topiramate, 56 weeks		Phentermine 7.5 mg plus topiramate 46 mg daily: −7.8%
Phentermine 15 mg plus topiramate 92 mg daily: −9.8%
Placebo (placebo): −1.2%
OASIS 4
Semaglutide, 64 weeks		Oral semaglutide 25 mg daily: −13.6%
Placebo (placebo): −2.2%
STEP 1
Semaglutide, 68 weeks		Semaglutide 2.4 mg weekly: −14.9%
Placebo (placebo): −2.4%
STEP 8
Semaglutide, 68 weeks		Semaglutide 2.4 mg weekly: −15.8%
Liraglutide 3.0 mg daily: −6.4%
Placebo (pooled) (placebo): −1.9%
STEP UP
Semaglutide, 72 weeks		Semaglutide 7.2 mg weekly: −18.7%
Semaglutide 2.4 mg weekly: −15.6%
Placebo (placebo): −3.9%
STEP 5
Semaglutide, 104 weeks		Semaglutide 2.4 mg weekly: −15.2%
Placebo (placebo): −2.6%
SURMOUNT-1
Tirzepatide, 72 weeks		Tirzepatide 5 mg weekly: −15.0%
Tirzepatide 10 mg weekly: −19.5%
Tirzepatide 15 mg weekly: −20.9%
Placebo (placebo): −3.1%
SURMOUNT-5
Tirzepatide, 72 weeks		Tirzepatide, highest tolerated dose (10 mg or 15 mg weekly): −20.2%
Semaglutide, highest tolerated dose (1.7 mg or 2.4 mg weekly): −13.7%
Pramlintide with phentermine (obesity)
Pramlintide, 24 weeks		Pramlintide 120 mcg three times daily: −3.7%
Pramlintide plus phentermine 37.5 mg: −11.3%
Placebo (placebo): −2.2%
REDEFINE 1
CagriSema, 68 weeks		CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) weekly: −20.4%
Placebo (placebo): −3.0%
REDEFINE 2
CagriSema, 68 weeks		CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) weekly: −13.7%
Placebo (placebo): −3.4%
Cagrilintide phase 2 (obesity)
Cagrilintide, 26 weeks		Cagrilintide, lowest result among the dose groups: −6.0%
Cagrilintide 4.5 mg weekly: −10.8%
Liraglutide 3.0 mg daily: −9.0%
Placebo (placebo): −3.0%
Eloralintide phase 2 (obesity)
Eloralintide, 48 weeks		Eloralintide 1 mg weekly: −9.0%
Eloralintide 3 mg weekly: −12.0%
Eloralintide 6 mg weekly: −18.0%
Eloralintide 9 mg weekly: −20.0%
Placebo (placebo): −0.4%
MariTide phase 2 (obesity)
Maridebart cafraglutide, 52 weeks		MariTide, lowest result among the dose groups: −12.3%
MariTide, highest result among the dose groups: −16.2%
Placebo (placebo): −2.5%
GLORY-1
Mazdutide, 48 weeks		Mazdutide 4 mg weekly: −11.0%
Mazdutide 6 mg weekly: −14.0%
Placebo (placebo): +0.3%
GLORY-2
Mazdutide, 60 weeks		Mazdutide 9 mg weekly: −16.6%
Placebo (placebo): −1.5%
MOMENTUM (pemvidutide, obesity)
Pemvidutide, 48 weeks		Pemvidutide 1.2 mg weekly: −10.3%
Pemvidutide 1.8 mg weekly: −11.2%
Pemvidutide 2.4 mg weekly: −15.6%
Placebo (placebo): −2.2%
ZUPREME-1 (petrelintide)
Petrelintide, 28 weeks		Petrelintide 1.0 mg weekly: −7.9%
Petrelintide 5.0 mg weekly: −9.8%
Petrelintide 9.0 mg weekly: −9.4%
Placebo (placebo): −1.7%
Retatrutide phase 2 (obesity)
Retatrutide, 48 weeks		Retatrutide 1 mg weekly: −8.7%
Retatrutide 4 mg weekly (groups combined): −17.1%
Retatrutide 8 mg weekly (groups combined): −22.8%
Retatrutide 12 mg weekly: −24.2%
Placebo (placebo): −2.1%
TRIUMPH-1
Retatrutide, 80 weeks		Retatrutide 4 mg weekly: −17.6%
Retatrutide 9 mg weekly: −23.7%
Retatrutide 12 mg weekly: −25.0%
Placebo (placebo): −3.9%
TRIUMPH-2
Retatrutide, 80 weeks		Retatrutide 4 mg weekly: −11.9%
Retatrutide 9 mg weekly: −16.8%
Retatrutide 12 mg weekly: −18.8%
Placebo (placebo): −5.1%
Survodutide phase 2 (obesity)
Survodutide, 46 weeks		Survodutide 0.6 mg weekly: −6.2%
Survodutide 2.4 mg weekly: −12.5%
Survodutide 3.6 mg weekly: −13.2%
Survodutide 4.8 mg weekly: −14.9%
Placebo (placebo): −2.8%
SYNCHRONIZE-1
Survodutide, 76 weeks		Survodutide, up to 3.6 mg weekly: −12.2%
Survodutide, up to 6.0 mg weekly: −13.0%
Placebo (placebo): −5.4%
SYNCHRONIZE-2
Survodutide, 76 weeks		Survodutide, 3.6 mg weekly: −8.2%
Survodutide, 6.0 mg weekly: −9.8%
Placebo (placebo): −3.9%
VENTURE (VK2735 injection)
VK2735, 13 weeks		VK2735 2.5 mg weekly: −9.1%
VK2735 15 mg weekly: −14.7%
Placebo (placebo): −1.7%
VENTURE-Oral (VK2735 tablet)
VK2735, 13 weeks		VK2735 15 mg daily: −2.3%
VK2735 30 mg daily: −7.0%
VK2735 60 mg daily: −8.7%
VK2735 90 mg daily: −11.1%
VK2735 120 mg daily: −12.2%
Placebo (placebo): −1.3%
Zenagamtide (amycretin) phase 1b/2a
Zenagamtide, 36 weeks		60 mg weekly (36 weeks): −24.3%
20 mg weekly (36 weeks): −22.0%
Placebo group for the 60 mg part (placebo): −1.1%

For charts with the comparison groups and limits, see trial results. For medicines still in testing, see the pipeline.

Sources for every trial

  1. Once-weekly semaglutide in adults with overweight or obesity (STEP 1) Wilding JPH, et al. N Engl J Med. 2021;384(11):989-1002. PMID 33567185. Funding: Novo Nordisk. Journal article
  2. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5) Garvey WT, et al. Nat Med. 2022;28(10):2083-2091. PMID 36216945. Funding: Novo Nordisk (authors include company employees). Journal article
  3. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4) Wharton S, et al. N Engl J Med. 2025;393(11):1077-1087. PMID 40934115. Funding: Novo Nordisk. Journal article
  4. FDA approves Wegovy pill, the first oral GLP-1 to treat obesity Healio. Trade press. Reports on-treatment OASIS 4 figures and how the pill is taken. Not the label. Trade press, secondary source
  5. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-216. PMID 35658024. Funding: Eli Lilly. Journal article
  6. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1) Wharton S, et al. N Engl J Med. 2025;393(18):1796-1806. PMID 40960239. Funding: Eli Lilly. Journal article
  7. ATTAIN-1 trial record (NCT05869903) ClinicalTrials.gov identifier NCT05869903. Trial registry
  8. Foundayo (orforglipron) tablets: prescribing information Eli Lilly and Company, on DailyMed (U.S. National Library of Medicine). Label version 7/2026. Official FDA label on DailyMed
  9. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526. PMID 37366315. Funding: Eli Lilly. Journal article
  10. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1) Jastreboff AM, et al. N Engl J Med. Published September 29, 2026. PMID 42814954. Funding: Eli Lilly. Journal article
  11. TRIUMPH-1 trial record (NCT05929066) ClinicalTrials.gov identifier NCT05929066. Trial registry
  12. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2) Bellido V, et al. Lancet. 2026;408(10563):1455-1472. PMID 42810372. Funding: Eli Lilly. Journal article
  13. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1) Garvey WT, et al. N Engl J Med. 2025;393(7):635-647. PMID 40544433. Funding: Novo Nordisk. Journal article
  14. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes (REDEFINE 2) Davies MJ, et al. N Engl J Med. 2025;393(7):648-659. PMID 40544432. Funding: Novo Nordisk. Journal article
  15. Once-monthly maridebart cafraglutide for the treatment of obesity, a phase 2 trial Jastreboff AM, et al. N Engl J Med. 2025;393(9):843-857. PMID 40549887. Funding: Amgen. Journal article
  16. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER) Gadde KM, et al. Lancet. 2011;377(9774):1341-1352. PMID 21481449. Funding: Vivus. Journal article
  17. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I) Greenway FL, et al. Lancet. 2010;376(9741):595-605. PMID 20673995. Funding: Orexigen Therapeutics. Journal article
  18. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial le Roux CW, et al. Lancet Diabetes Endocrinol. 2024;12(3):162-173. PMID 38330987. Funding: Boehringer Ingelheim. Journal article
  19. Survodutide once weekly for the treatment of adults with obesity (SYNCHRONIZE-1) le Roux CW, et al. N Engl J Med. 2026;395(8):776-787. PMID 42253238. Funding: Boehringer Ingelheim. Journal article
  20. Survodutide once weekly in adults with obesity and type 2 diabetes (SYNCHRONIZE-2) Wharton S, et al. N Engl J Med. 2026. PMID 42820639. Funding: Boehringer Ingelheim. Journal article
  21. Once-weekly mazdutide in Chinese adults with obesity or overweight (GLORY-1) Ji L, et al. N Engl J Med. 2025;392(22):2215-2225. PMID 40421736. Funding: Innovent Biologics. Journal article
  22. Treatment with 9-mg mazdutide for weight reduction in Chinese adults with obesity: the GLORY-2 randomized clinical trial Gao L, et al. JAMA. 2026;336(5):377-388. PMID 42251595. Funding: Innovent Biologics (trial sponsor). Journal article
  23. GLORY-2 trial record (NCT06164873) ClinicalTrials.gov identifier NCT06164873. Sponsor: Innovent Biologics. Trial registry
  24. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial Lau DCW, et al. Lancet. 2021;398(10317):2160-2172. PMID 34798060. Funding: Novo Nordisk. Journal article
  25. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial Billings LK, et al. Lancet. 2025;406(10520):2631-2643. PMID 41207310. Funding: Eli Lilly. Journal article
  26. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial Garvey WT, et al. Lancet Diabetes Endocrinol. 2026;14(11):914-926. PMID 42810355. Funding: Zealand Pharma. Journal article
  27. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study Dahl K, et al. Lancet. 2025;406(10499):149-162. PMID 40550231. Funding: Novo Nordisk. Journal article
  28. Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study Bays HE, et al. Obesity (Silver Spring). 2026;34(3):537-549. PMID 41508550. Funding: Not stated in the abstract. Several authors are Viking Therapeutics employees. Journal article
  29. Viking Therapeutics announces positive top-line results from phase 2 VENTURE-Oral dosing trial of VK2735 tablet formulation in patients with obesity Viking Therapeutics press release, August 19, 2025. Company announcement; not peer reviewed. Trade press, secondary source
  30. Altimmune announces positive topline results from MOMENTUM 48-week phase 2 obesity trial of pemvidutide Altimmune press release, November 30, 2023. Company announcement; not peer reviewed. Trade press, secondary source
  31. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects Cercato C, et al. Int J Obes (Lond). 2009;33(8):857-865. PMID 19564877. Funding: Not stated in the abstract. Journal article
  32. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial Aronne LJ, et al. Obesity (Silver Spring). 2010;18(9):1739-1746. PMID 20094043. Funding: Not stated in the abstract. Journal article
  33. Utilization of low-dose phentermine for weight loss prior to metabolic and bariatric surgery: a prospective, randomized, and placebo-controlled trial Garcia L, Rivas H, Morton J. Obes Sci Pract. 2025;11(1):e70043. PMID 39830713. Journal article
  34. Lomaira (phentermine hydrochloride) tablets: prescribing information KVK-Tech, Inc., on DailyMed (U.S. National Library of Medicine). FDA-approved label revised 12/2023. Official FDA label on DailyMed
  35. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5) Aronne LJ, et al. N Engl J Med. 2025;393(1):26-36. PMID 40353578. Funding: Eli Lilly. Journal article
  36. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes (STEP 8) Rubino DM, et al. JAMA. 2022;327(2):138-150. PMID 35015037. Funding: Novo Nordisk. Journal article
  37. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP) Wharton S, et al. Lancet Diabetes Endocrinol. 2025;13(11):949-963. PMID 40961952. Funding: Novo Nordisk. Journal article
  38. Wegovy HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss Novo Nordisk company announcement, March 19, 2026. Company announcement; not peer reviewed. Company announcement, not peer reviewed